Ultragenyx Pharmaceutical Stock Income Statements

Ultragenyx Pharmaceutical Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Ultragenyx Pharmaceutical Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31

revenues:
product sales	80,817,000	91,507,000	71,870,000	77,251,000	73,805,000	62,489,000	51,656,000	42,349,000	42,179,000	44,229,000	28,908,000	32,503,000	30,832,000	26,684,000	20,208,000	21,950,000	18,346,000	16,513,000	12,960,000	11,215,000	8,066,000	6,479,000	7,170,000	4,215,000	4,902,000	3,934,000	3,464,000	2,748,000	2,275,000	1,315,000
royalty revenue	85,679,000	47,785,000	93,007,000	62,243,000	73,221,000	46,344,000	75,736,000	55,703,000	46,331,000	4,882,000
total revenues	166,496,000	139,292,000	164,877,000	139,494,000	147,026,000	108,833,000	127,392,000	98,052,000	108,309,000	100,496,000	103,348,000	90,703,000	89,343,000	79,935,000	83,389,000	81,647,000	86,975,000	99,395,000	91,542,000	81,470,000	61,709,000	36,309,000	35,593,000	25,800,000	24,149,000	18,172,000	16,261,000	11,763,000	12,794,000	10,677,000
yoy	13.24%	27.99%	29.42%	42.27%	35.75%	8.30%	23.27%	8.10%	21.23%	25.72%	23.93%	11.09%	2.72%	-19.58%	-8.91%	0.22%	40.94%	173.75%	157.19%	215.78%	155.53%	99.81%	118.89%	119.33%	88.75%	70.20%
qoq	19.53%	-15.52%	18.20%	-5.12%	35.09%	-14.57%	29.92%	-9.47%	7.77%	-2.76%	13.94%	1.52%	11.77%	-4.14%	2.13%	-6.13%	-12.50%	8.58%	12.36%	32.02%	69.96%	2.01%	37.96%	6.84%	32.89%	11.75%	38.24%	-8.06%	19.83%
operating expenses:
cost of sales	23,002,000	28,662,000	16,894,000	21,021,000	21,280,000	17,533,000	12,051,000	10,987,000	9,914,000	12,257,000	5,319,000	8,631,000	8,270,000	6,100,000	3,509,000	4,175,000	3,136,000	5,188,000	5,481,000	2,348,000	1,803,000	-3,503,000	5,107,000	2,683,000	766,000	452,000	507,000	273,000	141,000	225,000
gross profit	143,494,000	110,630,000	147,983,000	118,473,000	125,746,000	91,300,000	115,341,000	87,065,000	98,395,000	88,239,000	98,029,000	82,072,000	81,073,000	73,835,000	79,880,000	77,472,000	83,839,000	94,207,000	86,061,000	79,122,000	59,906,000	32,806,000	30,486,000	23,117,000	23,383,000	17,720,000	15,754,000	11,490,000	12,653,000	10,452,000
yoy	14.11%	21.17%	28.30%	36.07%	27.80%	3.47%	17.66%	6.08%	21.37%	19.51%	22.72%	5.94%	-3.30%	-21.62%	-7.18%	-2.09%	39.95%	187.16%	182.30%	242.27%	156.19%	85.14%	93.51%	101.19%	84.80%	69.54%
qoq	29.71%	-25.24%	24.91%	-5.78%	37.73%	-20.84%	32.48%	-11.51%	11.51%	-9.99%	19.44%	1.23%	9.80%	-7.57%	3.11%	-7.59%	-11.01%	9.47%	8.77%	32.08%	82.61%	7.61%	31.88%	-1.14%	31.96%	12.48%	37.11%	-9.19%	21.06%
gross margin %	86.18%	79.42%	89.75%	84.93%	85.53%	83.89%	90.54%	88.79%	90.85%	87.80%	94.85%	90.48%	90.74%	92.37%	95.79%	94.89%	96.39%	94.78%	94.01%	97.12%	97.08%	90.35%	85.65%	89.60%	96.83%	97.51%	96.88%	97.68%	98.90%	97.89%
research and development	164,736,000	165,772,000	187,766,000	170,109,000	161,503,000	178,487,000	160,557,000	157,245,000	164,949,000	165,698,000	170,808,000	237,297,000	154,529,000	143,155,000	123,013,000	113,417,000	113,205,000	147,518,000	131,100,000	87,314,000	80,709,000	112,961,000	83,061,000	100,144,000	96,045,000	78,105,000	71,618,000	70,041,000	76,835,000	75,504,000	61,527,000	60,412,000	58,436,000	51,269,000	50,746,000	48,711,000	43,332,000	40,415,000	44,565,000	29,704,000	23,104,000	17,364,000	13,521,000	12,854,000	11,239,000	8,353,000
selling, general and administrative	86,646,000	87,797,000	82,495,000	80,351,000	80,604,000	78,160,000	76,833,000	74,917,000	81,403,000	76,646,000	72,849,000	69,841,000	68,137,000	67,312,000	59,431,000	53,883,000	53,410,000	53,258,000	51,042,000	42,123,000	42,252,000	47,516,000	41,877,000	41,006,000	39,812,000	38,829,000	34,476,000	31,095,000	30,718,000	31,435,000
total operating expenses	274,384,000	282,231,000	287,155,000	271,481,000	263,387,000	274,180,000	249,441,000	243,149,000	256,266,000	254,601,000	248,976,000	315,769,000	230,936,000	216,567,000	185,953,000	171,475,000	169,751,000	205,964,000	187,623,000	131,785,000	124,764,000	156,974,000	130,045,000	143,833,000	136,623,000	117,386,000	106,601,000	101,409,000	107,694,000	107,164,000	99,248,000	83,911,000	78,441,000	69,954,000	70,554,000	65,894,000	58,070,000	53,622,000	56,158,000	39,936,000	30,142,000	21,502,000	16,943,000	15,835,000	13,661,000	10,339,000
income from operations	-107,888,000	-142,939,000	-122,278,000	-131,987,000	-116,361,000	-165,347,000	-122,049,000	-145,097,000	-147,957,000	-154,105,000	-145,628,000	-225,066,000	-141,593,000	-136,632,000	-102,564,000	-89,828,000	-82,776,000	-106,569,000	-96,081,000	-50,315,000	-63,055,000	-120,665,000	-94,452,000	-118,033,000	-112,474,000	-99,214,000	-90,340,000	-89,646,000	-94,900,000	-96,487,000	-96,834,000	-83,713,000	-78,441,000	-69,954,000	-70,549,000	-65,783,000	-58,053,000	-53,622,000	-56,158,000	-39,936,000	-30,142,000	-21,502,000	-16,943,000	-15,835,000	-13,661,000	-10,339,000
yoy	-7.28%	-13.55%	0.19%	-9.04%	-21.35%	7.30%	-16.19%	-35.53%	4.49%	12.79%	41.99%	150.55%	71.06%	28.21%	6.75%	78.53%	31.28%	-11.68%	1.72%	-57.37%	-43.94%	21.62%	4.55%	31.67%	18.52%	2.83%	-6.71%	7.09%	20.98%	37.93%	37.26%	27.26%	35.12%	30.46%	25.63%	64.72%	92.60%	149.38%	231.45%	152.20%	120.64%	107.97%
qoq	-24.52%	16.90%	-7.36%	13.43%	-29.63%	35.48%	-15.88%	-1.93%	-3.99%	5.82%	-35.30%	58.95%	3.63%	33.22%	14.18%	8.52%	-22.33%	10.92%	90.96%	-20.20%	-47.74%	27.75%	-19.98%	4.94%	13.37%	9.82%	0.77%	-5.54%	-1.64%	-0.36%	15.67%	6.72%	12.13%	-0.84%	7.25%	13.32%	8.26%	-4.52%	40.62%	32.49%	40.18%	26.91%	7.00%	15.91%	32.13%
operating margin %	-64.80%	-102.62%	-74.16%	-94.62%	-79.14%	-151.93%	-95.81%	-147.98%	-136.61%	-153.34%	-140.91%	-248.14%	-158.48%	-170.93%	-122.99%	-110.02%	-95.17%	-107.22%	-104.96%	-61.76%	-102.18%	-332.33%	-265.37%	-457.49%	-465.75%	-545.97%	-555.56%	-762.10%	-741.75%	-903.69%
interest income	5,794,000	6,831,000	9,550,000	10,731,000	7,401,000	8,824,000	8,553,000	5,881,000	5,964,000	6,290,000	6,198,000	3,483,000	899,000	494,000	440,000	408,000	441,000	639,000	984,000	1,338,000	1,797,000	2,919,000	2,770,000	3,319,000	4,063,000	3,086,000	2,627,000	2,730,000	2,448,000	1,737,000	724,000	1,117,000	1,151,000	1,082,000	912,000	922,000	971,000	984,000	918,000	673,000	456,000	273,000	195,000	171,000	149,000	93,000
change in fair value of equity investments	-9,000	-157,000	-1,548,000	678,000	-3,991,000	3,746,000	1,889,000	-1,419,000	261,000	-334,000	1,840,000	-1,626,000	-10,184,000	-9,329,000	-16,100,000	25,702,000	-31,046,000	-20,619,000
non-cash interest expense on liabilities for sales of future royalties	-14,041,000	-14,342,000	-15,522,000	-15,712,000	-15,960,000	-15,847,000	-17,328,000	-17,665,000	-15,375,000	-15,636,000
other income	2,140,000	837,000	-3,606,000	3,077,000	-1,829,000	-1,605,000	2,043,000	-699,000	-1,989,000	308,000	180,000	-1,105,000	-930,000	289,000	-410,000	-415,000	-67,000	-795,000	299,000	547,000	217,000	-456,000	154,000	-153,000	-376,000	-412,000	13,000	-147,000	-496,000	-4,958,000	-1,838,000	3,373,000	4,413,000	582,000	-1,615,000	-46,000	159,000	-119,000	20,000	31,000	-101,000	-150,000	10,000	-185,000	-73,000	-3,384,000
income before income taxes	-114,004,000	-149,770,000	-133,404,000	-133,213,000	-130,740,000	-170,229,000	-126,892,000	-158,999,000	-159,096,000	-163,477,000	-153,284,000	-238,819,000	-157,860,000	-151,762,000	-122,438,000	-72,816,000	-121,965,000	-135,762,000	-23,941,000	-68,532,000	25,730,000	-118,616,000	-91,244,000	-112,701,000	-98,959,000	-96,540,000	-87,700,000	-87,063,000	-52,626,000	30,292,000	-97,948,000	-79,223,000	-72,877,000
benefit from income taxes	-947,000	-1,310,000	-404,000	-303,000	-858,000	-455,000	3,702,000	-650,000	-732,000	-495,000	1,451,000	-6,287,000	-302,000	-558,000	-20,000	-182,000	-463,000	-379,000	-70,000	-313,000	-415,000	-409,000	-2,561,000	-293,000	-213,000	-216,000	-126,000	-247,000	-102,000	-39,000
net income	-114,951,000	-151,080,000	-133,385,000	-133,516,000	-131,598,000	-170,684,000	-123,190,000	-159,649,000	-159,828,000	-163,972,000	-151,833,000	-245,106,000	-158,162,000	-152,320,000	-122,458,000	-72,998,000	-122,428,000	-136,141,000	-24,011,000	-68,845,000	25,315,000	-119,025,000	-93,805,000	-112,994,000	-99,172,000	-96,756,000	-87,826,000	-87,310,000	-52,728,000	30,253,000	-81,731,000	-79,227,000	-72,891,000	-68,290,000	-71,287,000	-64,907,000	-56,923,000	-52,757,000	-55,220,000	-39,232,000	-29,787,000	-21,379,000	-16,738,000	-15,849,000	-13,585,000	-13,630,000
yoy	-12.65%	-11.49%	8.28%	-16.37%	-17.66%	4.09%	-18.86%	-34.87%	1.05%	7.65%	23.99%	235.77%	29.19%	11.88%	410.01%	6.03%	-583.62%	14.38%	-74.40%	-39.07%	-125.53%	23.02%	6.81%	29.42%	88.08%	-419.82%	7.46%	10.20%	-27.66%	-144.30%	14.65%	22.06%	28.05%	29.44%	29.10%	65.44%	91.10%	146.77%	229.91%	147.54%	119.26%	56.85%
qoq	-23.91%	13.27%	-0.10%	1.46%	-22.90%	38.55%	-22.84%	-0.11%	-2.53%	7.99%	-38.05%	54.97%	3.84%	24.39%	67.76%	-40.37%	-10.07%	466.99%	-65.12%	-371.95%	-121.27%	26.89%	-16.98%	13.94%	2.50%	10.17%	0.59%	65.59%	-274.29%	-137.02%	3.16%	8.69%	6.74%	-4.20%	9.83%	14.03%	7.90%	-4.46%	40.75%	31.71%	39.33%	27.73%	5.61%	16.67%	-0.33%
net income margin %	-69.04%	-108.46%	-80.90%	-95.71%	-89.51%	-156.83%	-96.70%	-162.82%	-147.57%	-163.16%	-146.91%	-270.23%	-177.03%	-190.55%	-146.85%	-89.41%	-140.76%	-136.97%	-26.23%	-84.50%	41.02%	-327.81%	-263.55%	-437.96%	-410.67%	-532.45%	-540.10%	-742.24%	-412.13%	283.35%
net income per share	-1.17	-1.57	-1.38	-1.4	-1.52	-2.03	-1.44	-2.23	-2.25	-2.33	-2.16	-3.5	-2.26	-2.19	-1.79	-1.08		-2.03	-0.34	-1.13		-2.05	-1.62	-1.96	-1.72		-1.75	-1.74	-1.06		-1.9	-1.87	-1.72	-1.63	-1.75	-1.64	-1.46	-1.35	-1.45	-1.03	-0.83	-0.63	-0.52	-0.5	-0.45	-0.85
shares used in computing net income per share, basic and diluted	98,460,445	96,288,650	1,726,961	95,493,996	86,580,516	84,286,292																57,995,999	414,889	57,707,694	57,519,308		327,334	50,319,772	49,819,528		230,722	42,471,606	42,346,830	41,841,612	9,796,248.5	39,551,923	39,028,701	38,970,151
collaboration and license									19,799,000	51,385,000	68,382,000	52,827,000	53,088,000	48,413,000	58,440,000	55,048,000	63,940,000	79,010,000	75,015,000	66,924,000	50,161,000	27,215,000	28,423,000	21,585,000	19,247,000	14,238,000	12,797,000	9,015,000	10,519,000	9,362,000
weighted-average shares used for eps calculation								71,664,493	70,897,991	70,368,478	69,914,225	70,054,173	69,925,358	69,516,668	67,795,540	67,875,363		67,102,342		60,687,177
non-cash collaboration royalty revenue											6,058,000	5,373,000	5,423,000	4,838,000	4,741,000	4,649,000	4,689,000	3,872,000	3,567,000	3,331,000	3,482,000	2,615,000
non-cash interest expense on liabilities related to the sale of future royalties											-6,785,250	-14,505,000
non-cash interest expense on liability related to the sale of future royalties													-6,052,000	-6,584,000	-3,804,000	-8,683,000	-8,517,000	-8,418,000	-8,198,000	-8,582,000	-8,429,000	-8,082,000
net income per share	-1.17	-1.57	-1.38	-1.4	-1.52	-2.03	-1.44	-2.23	-2.25	-2.33	-2.16	-3.5	-2.26	-2.19	-1.79	-1.08		-2.03	-0.34	-1.13		-2.05	-1.62	-1.96	-1.72		-1.75	-1.74	-1.06		-1.9	-1.87	-1.72	-1.63	-1.75	-1.64	-1.46	-1.35	-1.45	-1.03	-0.83	-0.63	-0.52	-0.5	-0.45	-0.85
basic																	-1.81				0.42					-1.82				0.63
diluted																	-1.81				0.41					-1.82				0.62
weighted-average shares used for eps calculation								71,664,493	70,897,991	70,368,478	69,914,225	70,054,173	69,925,358	69,516,668	67,795,540	67,875,363		67,102,342		60,687,177
basic																	67,607,752				59,995,617
diluted																	67,607,752				61,146,231
change in fair value of investments in equity securities																			22,837,000	-11,520,000
change in fair value of investment in arcturus equity securities																					95,200,000	7,668,000	1,419,000	2,166,000	9,828,000
gain from sale of priority review vouchers																													40,322,000
gain from sale of priority review voucher																														130,000,000
shares used in computing net income per share:
basic																										53,209,215				48,190,511
diluted																										53,209,215				49,077,742
other income, net:
revenue																															49,500	198,000			5,000	111,000	17,000
general and administrative																															15,547,250	23,499,000	20,005,000	18,685,000	19,808,000	17,183,000	14,738,000	13,207,000	11,593,000	10,232,000	7,038,000	4,138,000	3,422,000	2,981,000	2,422,000	1,986,000
total other income																															2,929,500	4,490,000	5,564,000	1,664,000	-703,000	876,000	1,130,000	865,000	938,000	704,000	355,000	123,000	205,000	-14,000	76,000	-3,291,000
income tax provision																															-4,500	-4,000	-14,000
net income attributable to common stockholders																																							-55,220,000	-39,232,000	-29,787,000	-21,379,000	-16,738,000	-15,849,000	-13,585,000	-18,438,000
shares used in computing net income per share attributable to common stockholders, basic and diluted																																							696,005	38,268,632	35,937,442	34,008,830	1,058,621	31,631,385	30,055,943	21,582,435
interest expense

We provide you with 20 years income statements for Ultragenyx Pharmaceutical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ultragenyx Pharmaceutical stock. Explore the full financial landscape of Ultragenyx Pharmaceutical stock with our expertly curated income statements.

The information provided in this report about Ultragenyx Pharmaceutical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.